PDA

View Full Version : CTIX - Cellceutix Corporation (OTCBB)



ciswjtbn23
07-04-2015,
I've been researching Cellceutix pretty heavily lately. Company is solid with a strong management team. Dr. Menon, who heads up the research team is nothing shy of brilliant. I will post more info on them as I learn it. Lower float play with most shares being held by insiders and the float being held relatively tightly by people that are optimistic about Cellceutix's future (according to CRO, Leo Ehrlich). A basic snapshot of Cellceutix:

Cellceutix Pharmaceuticals, Inc. (OTCBB: CTIX), located outside of Boston in Beverly, MA, is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Their primary efforts are in cancer and inflammatory disease, but also have another product in the pipeline that is being formulated to treat autism. Cellceutix flagship product, Kevetrin, is being developed to treat cancers that are resistant to standard treatments. Recently, Cellceutix has announced some exciting results in animal models of multi-drug resistant lung cancer.

Their business strategy is well-described by their company slogan “Compounds for Cures.” Cellceutix has kept a “low profile” as they have been developing their products with the ethical philosophy of their products alone will help patients and this will translate into rewards for shareholders. By biotechnology standards, their pipeline of products is moving forward rapidly through an experienced management and development team with years of experience in researching, developing and marketing pharmaceuticals. By “Over The Counter Bulletin Board” standards, their ethics are virtually unparalleled.

To quote the Cellceutix CEO, George Evans:
“Biotech companies have a tendency to talk excitedly about a lot of very complicated science. The excitement is, of course, genuine as the companies see great promise in what they are doing. But how do we understand what it all means? Just like a lot of other companies, we are doing a lot of very complicated experiments and coming up with a lot of dense data and great graphs. And we really like what we see. I think in our case, however, it is easy to explain what it all means. First, it means that we’ve accomplished a lot in a short time. And second it means that our lead compound, Kevetrin, is showing great promise in treating tumors that are otherwise very difficult to treat. This means hope for patients and value for shareholders.”

chonfilyclown
07-04-2015,
Press Release Source: Cellceutix On Monday March 29, 2010, 6:00 am
BEVERLY, MA--(Marketwire - 03/29/10) - Cellceutix Corporation (OTC.BB:CTIX - News), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the "no treatment" group and the "active control" (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

"We are extremely excited about the data on KM-391 and the potential for the compound in this area of urgent medical need," said George Evans, CEO of Cellceutix. "Diagnoses of autism are rising dramatically and the disease takes a terrible toll on families. There is a critical need for new treatments for autism and we are pleased to be part of the effort to find them."

"Research on autism has been difficult because there has been no reliable animal model," said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. "Fortunately, we were able to tap into some cutting edge research to find a promising model for our study."

An audio link discussing this event is at:

cellceutix - Press Release Audio 3-29-2010

For more details about KM-391and the study, please visit the Cellceutix web site at cellceutix - Home.

About Autism Spectrum Disorders:

Autism is a behavior disorder, characterized by an impairment in social communication, social interaction, and social imagination. Those with autism often have a restricted range of interests and display repetitive behaviors and mannerisms, along with altered reactions to the everyday environment.

Cliftonnole
07-04-2015,
The big spread on CTIX is certainly being a pain. It finally chewed through the ask at .48 and it moved to .55, but the bid is remaining at .28. Actually, it just upticked to move the bid to .29. Long term play, but I still would like to see the spread tighten.
__________________
"Always bear in mind that your own resolution to success is more important than any other one thing." - Abraham Lincoln

"The heights by great men reached and kept, were not obtained by sudden flight. But they, while their companions slept, were toiling upward in the night." - Longfellow

"If the life you have created
Is founded on jealousy and hatred...
It's too late to ask questions
For you're much too old to take any suggestions"

Full Disclosure

cikewulohm
07-05-2015,
Cellceutix CEO, George Evans, interviewed on "Stu Taylor on Business" Radio Show. The audio is available at: http://www.cellceutix.com/Stu_Taylor_Mar-30-2010.wma
Go to 30 minutes into the show to hear about the Cellceutix growth and development of Kevetrin, their cancer drug, and KM-391, their drug being developed for autism.

Press Release from today:

Cellceutix CEO Appears on ‘Stu Taylor on Business’: Cancer and Autism Compounds Are Discussed
BEVERLY, MA–(Marketwire – April 12, 2010) – Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that its CEO, George Evans, appeared on the radio program Stu Taylor on Business on Saturday evening. Mr. Evans discussed a range of issues regarding the Cellceutix portfolio of compounds. Kevetrin™, which is being developed to treat drug resistant cancers, and KM-391, which is being developed to treat autism spectrum disorder were prominently featured. Please visit the Cellceutix web site at cellceutix - Home for a link to the program.
“This type of program is a great opportunity for companies like Cellceutix to get the word out about our important research efforts,” said Mr. Evans. “We are going to keep looking for these chances to tell our story.”
In animal studies, Kevetrin has been found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. On April 20, Cellceutix will be presenting a poster of important new data on Kevetrin at the American Association for Cancer Research (AACR) in Washington, DC. More information about these studies and the AACR presentation is available on the Cellceutix web site at cellceutix - Home.
KM-391, Cellceutix’s novel compound in development for the treatment of autism, was shown to improve several key parameters in an animal model of autism. Given the urgent medical need in this area, the Company is working as rapidly as possible to move KM-391 toward human studies. The pharmaceutical industry is only recently gearing up to develop drugs that address the primary conditions of autism. At Cellceutix we hope to stay ahead of the curve on autism research.
About Cellceutix

CHoto
07-05-2015,
Cellceutix Signs Agreements for KevetrinTM Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers

BEVERLY, MA--(Marketwire - May 24, 2010) - Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that it has concluded agreements with PharPoint Reasearch for Phase 1 data management and statistical analysis and with Medical Research Consulting Services for Phase 1 clinical monitoring. The terms of the agreements were not disclosed. These agreements provide the basic resources necessary to conduct the Phase 1 study of the Company's cancer compound, Kevetrin.

"We were looking for elite partners that could provide world class service and with PharPoint and Medical Research Consulting Services we have come to terms with two of the best in the industry," said George Evans, CEO of Cellceutix. "These agreements are the next step in our mission to start the Phase 1 study of Kevetrin ASAP."

"We are pleased to have the opportunity to work with Cellceutix and to bring our skills to bear on the Kevetrin Phase 1 study," said Art Holmes, President of PharPoint. Mr. Holmes continued, "From a corporate standpoint, it is exciting to be involved in the start of a promising clinical program, particularly in the field of oncology where there is an urgent need for new therapies." More information about PharPoint is available at PharPoint Research.

Kevetrin is being developed to treat drug resistant cancers. The Company has reported that Kevetrin showed greater tumor growth delay than standard therapies in animal models of resistant lung cancer, resistant breast cancer and resistant colon cancer. In data recently presented at the American Association for Cancer Research (AACR), the efficacy of Kevetrin in a mouse model of drug resistant lung cancer was shown to increase with increasing dose. The data presented at the AACR also show that the administration of a second cycle of therapy with Kevetrin in the same animal model continues to delay tumor growth without the development of resistance. For more information about these results, please visit the Cellceutix web site at cellceutix - Home.

"I am looking forward to working with Cellceutix on the Phase I clinical trial of their novel development product, Kevetrin, for the treatment of solid carcinomas," said Denise T. Resnik, the Owner of Medical Research Consulting Services. "I have had a long-standing consulting relationship with George Evans's prior employer, and I am sure this relationship will be fruitful as well."

About PharPoint Research

admin
07-06-2015,
Jun 03, 2010 08:35 ET
Cellceutix CFO Discusses Autism Drug, KevetrinTM and Company Progressions With CEOCFO Interviews and News

BEVERLY, MA--(Marketwire - June 3, 2010) - Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. The interview was conducted by CEOCFO Senior Editor Lynn Fosse and highlighted the uniqueness of Cellceutix and the details that make it stand out from all other biotechnology companies in the industry.

In the interview, Mr. Ehrlich discusses the progressions of KM-391, Cellceutix's compound for the treatment of autism, and Kevetrin, their drug being developed as a treatment for drug-resistant cancers. Mr. Ehrlich explained why their autism drug is revolutionary as there is no drug available today for the treatment of autism. Additionally, Mr. Ehrlich also discusses the company's growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.

"We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market," Mr. Ehrlich explained. "Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound."

"We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy," commented Mr. Ehrlich.

The interview is available at:
http://www.cellceutix.com/CTIX-Cellc...nges-Color.pdf

http://ceocfointerviews.com

About CEOCFO Interviews & News